Alnylam Pharmaceuticals Aktie
235,60
EUR
+0,90
EUR
+0,38
%
246,36
USD
-2,74
USD
-1,10
%
Werbung
Alnylam Pharmaceuticals Aktie Analyse
30.03.17 | Alnylam Pharmaceuticals Neutral | UBS AG | |
24.11.09 | Alnylam Pharmaceuticals hold | ROTH Capital Partners, LLC | |
26.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
25.02.09 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
15.09.08 | Alnylam Pharmaceuticals market weight | Thomas Weisel Partners LLC | |
21.08.08 | Alnylam Pharmaceuticals | Focus Money | |
10.10.07 | Alnylam Pharmaceuticals market perform | Piper Jaffray & Co. | |
14.08.07 | Alnylam Pharmaceuticals hold | Needham & Company, LLC | |
Werbung
|
Werbung